HRP20210020T1 - Ligand a3 adenozinskog receptora za primjenu u liječenju nagomilavanja ektopične masnoće - Google Patents
Ligand a3 adenozinskog receptora za primjenu u liječenju nagomilavanja ektopične masnoće Download PDFInfo
- Publication number
- HRP20210020T1 HRP20210020T1 HRP20210020TT HRP20210020T HRP20210020T1 HR P20210020 T1 HRP20210020 T1 HR P20210020T1 HR P20210020T T HRP20210020T T HR P20210020TT HR P20210020 T HRP20210020 T HR P20210020T HR P20210020 T1 HRP20210020 T1 HR P20210020T1
- Authority
- HR
- Croatia
- Prior art keywords
- a3ar
- adenosine
- ligand
- administration
- a3ar ligand
- Prior art date
Links
- 101150046889 ADORA3 gene Proteins 0.000 title claims 12
- 239000003446 ligand Substances 0.000 title claims 9
- 238000009825 accumulation Methods 0.000 title 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- IPSYPUKKXMNCNQ-PFHKOEEOSA-N (2s,3s,4r,5r)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC(Cl)=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 IPSYPUKKXMNCNQ-PFHKOEEOSA-N 0.000 claims 2
- HUJXGQILHAUCCV-MOROJQBDSA-N 3-iodobenzyl-5'-N-methylcarboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 HUJXGQILHAUCCV-MOROJQBDSA-N 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- XTPOZVLRZZIEBW-SCFUHWHPSA-N (2r,3r,4s,5r)-2-[6-[2-(4-aminophenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=CC(N)=CC=C1CCNC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XTPOZVLRZZIEBW-SCFUHWHPSA-N 0.000 claims 1
- LDYMCRRFCMRFKB-MOROJQBDSA-N (2s,3s,4r,5r)-5-[6-[(4-aminophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=CC(N)=CC=3)=C2N=C1 LDYMCRRFCMRFKB-MOROJQBDSA-N 0.000 claims 1
- 208000008784 apnea Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 claims 1
- 230000006372 lipid accumulation Effects 0.000 claims 1
- 210000005228 liver tissue Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Claims (7)
1. Agonist A3 adenozinskog receptora (A3AR) za primjenu u smanjenju lipidne akumulacije u tkivu jetre subjekta koji ima nealkoholnu masnu bolest jetre (NAFLD - non-alcoholic fatty liver disease), pri čemu navedeni A3AR agonist je odabran iz grupe koja se sastoji od N6-2-(4-aminofenil)etil adenozina (APNEA), N6-(4-amino-3-jodobenzil)adenozin-5'-(N-metiluronamida) (AB-MECA), N6-(3-jodobenzil)-adenozin-5'-N-metiluronamida (IB-MECA) i 2-kloro-N6-(3-jodobenzil)-adenozin-5'-N-metiluronamida (CI-IB-MECA).
2. A3AR ligand za primjenu iz patentnog zahtjeva 1 pri čemu količina je efikasna za smanjenje nivoa barem triglicerida u navedenom tkivu.
3. A3AR ligand za primjenu iz patentnog zahtjeva 1 ili 2, pri čemu navedeno liječenje obuhvaća dnevnu administraciju navedenog A3AR liganda navedenom subjektu.
4. A3AR ligand za primjenu iz bilo kojeg od patentnih zahtjeva 1 do 3, pri čemu navedeno liječenje obuhvaća kroničnu administraciju navedenog A3AR liganda.
5. A3AR ligand za primjenu iz bilo kojeg od patentnih zahtjeva 1 do 4, pri čemu navedena administracija je oralna administracija.
6. A3AR ligand za primjenu iz bilo kojeg od patentnih zahtjeva 1 do 5, pri čemu navedena administracija je jednom ili dva puta na dan.
7. A3AR ligand iz bilo kojeg od patentnih zahtjeva 1 do 6, za primjenu u liječenju nealkoholnog steatohepatitisa (NASH).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL242723A IL242723B (en) | 2015-11-23 | 2015-11-23 | A3 adenosine receptor ligand for the treatment of ectopic fat accumulation |
| PCT/IL2016/051258 WO2017090036A1 (en) | 2015-11-23 | 2016-11-22 | An a3 adenosine receptor ligand for use in treating ectopic fat accumulation |
| EP16806299.0A EP3380104B1 (en) | 2015-11-23 | 2016-11-22 | An a3 adenosine receptor ligand for use in treating ectopic fat accumulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210020T1 true HRP20210020T1 (hr) | 2021-03-05 |
Family
ID=57485841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210020TT HRP20210020T1 (hr) | 2015-11-23 | 2021-01-07 | Ligand a3 adenozinskog receptora za primjenu u liječenju nagomilavanja ektopične masnoće |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10780106B2 (hr) |
| EP (1) | EP3380104B1 (hr) |
| JP (2) | JP6980655B2 (hr) |
| KR (1) | KR102103657B1 (hr) |
| CN (1) | CN108367016B (hr) |
| BR (1) | BR112018010391A8 (hr) |
| CA (1) | CA3005961A1 (hr) |
| DK (1) | DK3380104T3 (hr) |
| ES (1) | ES2848150T3 (hr) |
| HR (1) | HRP20210020T1 (hr) |
| HU (1) | HUE053558T2 (hr) |
| IL (3) | IL242723B (hr) |
| LT (1) | LT3380104T (hr) |
| MX (1) | MX2018006026A (hr) |
| PL (1) | PL3380104T3 (hr) |
| PT (1) | PT3380104T (hr) |
| RS (1) | RS61372B1 (hr) |
| SI (1) | SI3380104T1 (hr) |
| WO (1) | WO2017090036A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL254535A0 (en) * | 2017-09-17 | 2017-11-30 | Can Fite Biopharma Ltd | Adenosine a3 receptor ligand for use in the management of cytokine release syndrome |
| IL264112A (en) * | 2019-01-06 | 2020-07-30 | Fishman Pnina | Adenosine a3 receptor ligand for use in lowering adipocyte levels |
| IL272078A (en) | 2020-01-16 | 2021-07-29 | Can Fite Biopharma Ltd | Cannabinoids for use in therapy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443836A (en) | 1993-03-15 | 1995-08-22 | Gensia, Inc. | Methods for protecting tissues and organs from ischemic damage |
| DE69428536T2 (de) | 1993-07-13 | 2002-06-06 | Nasa | A3 -adenosin -rezeptor agonisten |
| US5688774A (en) | 1993-07-13 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
| WO1997027173A2 (en) | 1996-01-24 | 1997-07-31 | Sumitomo Chemical Company, Limited | Dihalopropene compounds, their use as insecticides/acaricides and intermediates for their production |
| US6048865A (en) | 1997-07-29 | 2000-04-11 | Medco Research, Inc. | N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator |
| JP2003517423A (ja) | 1997-07-29 | 2003-05-27 | メドコ リサーチ、インコーポレイテッド | アデノシンレセプターモジュレーターとしてのｎ６−置換アデノシン−５′−ウロナミド |
| AU1363699A (en) | 1997-10-23 | 1999-05-10 | National Institute Of Health | Methods for reducing ischemic injury of the heart via the sequential administ ration of monophosphoryl lipid a and adenosine receptor agents |
| IL133680A0 (en) | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| US7589075B2 (en) | 2001-01-16 | 2009-09-15 | Can-Fite Biopharma Ltd. | Use of an adenosine A3 receptor agonist for inhibition of viral replication |
| CN101410114B (zh) | 2006-01-26 | 2012-07-04 | 美国政府卫生与公共服务部 | A3腺苷受体别构调节剂 |
| ES2490606T3 (es) * | 2007-10-15 | 2014-09-04 | Can-Fite Biopharma Ltd. | Procedimiento para inducir proliferación de hepatocitos y usos del mismo |
| WO2013111132A1 (en) * | 2012-01-23 | 2013-08-01 | Can-Fite Biopharma Ltd. | Treatment of liver conditions |
-
2015
- 2015-11-23 IL IL242723A patent/IL242723B/en active IP Right Grant
-
2016
- 2016-11-22 SI SI201631045T patent/SI3380104T1/sl unknown
- 2016-11-22 ES ES16806299T patent/ES2848150T3/es active Active
- 2016-11-22 KR KR1020187016840A patent/KR102103657B1/ko active IP Right Grant
- 2016-11-22 HU HUE16806299A patent/HUE053558T2/hu unknown
- 2016-11-22 EP EP16806299.0A patent/EP3380104B1/en active Active
- 2016-11-22 MX MX2018006026A patent/MX2018006026A/es unknown
- 2016-11-22 DK DK16806299.0T patent/DK3380104T3/da active
- 2016-11-22 LT LTEP16806299.0T patent/LT3380104T/lt unknown
- 2016-11-22 BR BR112018010391A patent/BR112018010391A8/pt not_active Application Discontinuation
- 2016-11-22 PT PT168062990T patent/PT3380104T/pt unknown
- 2016-11-22 IL IL289841A patent/IL289841B/en unknown
- 2016-11-22 WO PCT/IL2016/051258 patent/WO2017090036A1/en active Application Filing
- 2016-11-22 JP JP2018526535A patent/JP6980655B2/ja active Active
- 2016-11-22 PL PL16806299T patent/PL3380104T3/pl unknown
- 2016-11-22 CN CN201680068558.0A patent/CN108367016B/zh active Active
- 2016-11-22 CA CA3005961A patent/CA3005961A1/en active Granted
- 2016-11-22 RS RS20210079A patent/RS61372B1/sr unknown
-
2018
- 2018-05-16 IL IL259396A patent/IL259396B/en unknown
- 2018-05-22 US US15/986,332 patent/US10780106B2/en active Active
-
2020
- 2020-02-10 JP JP2020020917A patent/JP6990934B2/ja active Active
- 2020-08-26 US US17/003,191 patent/US11291681B2/en active Active
-
2021
- 2021-01-07 HR HRP20210020TT patent/HRP20210020T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT3380104T (lt) | 2021-05-10 |
| IL259396B (en) | 2022-02-01 |
| MX2018006026A (es) | 2019-01-28 |
| US20180264022A1 (en) | 2018-09-20 |
| EP3380104B1 (en) | 2020-11-11 |
| US20200384009A1 (en) | 2020-12-10 |
| RS61372B1 (sr) | 2021-02-26 |
| IL259396A (en) | 2018-07-31 |
| JP2020090532A (ja) | 2020-06-11 |
| DK3380104T3 (da) | 2021-02-08 |
| WO2017090036A1 (en) | 2017-06-01 |
| JP6980655B2 (ja) | 2021-12-15 |
| CN108367016A (zh) | 2018-08-03 |
| BR112018010391A8 (pt) | 2019-02-26 |
| IL242723B (en) | 2019-12-31 |
| JP6990934B2 (ja) | 2022-01-12 |
| PL3380104T3 (pl) | 2021-08-02 |
| KR102103657B1 (ko) | 2020-04-23 |
| PT3380104T (pt) | 2021-02-05 |
| BR112018010391A2 (pt) | 2018-11-21 |
| CN108367016B (zh) | 2021-07-16 |
| CA3005961A1 (en) | 2017-06-01 |
| IL242723A0 (en) | 2016-02-29 |
| JP2018534333A (ja) | 2018-11-22 |
| ES2848150T3 (es) | 2021-08-05 |
| KR20180081595A (ko) | 2018-07-16 |
| US10780106B2 (en) | 2020-09-22 |
| IL289841B (en) | 2022-07-01 |
| EP3380104A1 (en) | 2018-10-03 |
| US11291681B2 (en) | 2022-04-05 |
| HUE053558T2 (hu) | 2021-07-28 |
| SI3380104T1 (sl) | 2021-05-31 |
| IL289841A (en) | 2022-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210020T1 (hr) | Ligand a3 adenozinskog receptora za primjenu u liječenju nagomilavanja ektopične masnoće | |
| HRP20221325T1 (hr) | Pripravci i postupci transmukozne apsorpcije | |
| BRPI0810177A2 (pt) | Métodos e sistemas para medição de fluxo sanguíneo usando tomografia de coerência doppler | |
| HRP20240231T1 (hr) | Farmaceutske formulacije inhibitora brutonove tirozin kinaze | |
| BR112017013196A2 (pt) | artigo absorvente com camada de folha superior em contato com a pele, parcialmente separável | |
| BR112017011338A2 (pt) | artigo absorvente descartável | |
| ES2970504T3 (es) | Uso de la microbiota intestinal en el diagnóstico de la enfermedad de Parkinson | |
| BR112017009218A2 (pt) | recursos de mudança automática de artigo absorvente | |
| FR3031514B1 (fr) | Composite de sels de sodium et d'ammonium pour la depollution des fumees | |
| FI20130323A (fi) | Menetelmä rasva- ja kolesterolivaihduntaa edistävän sekä rasvakudoksen määrää vähentävän liikunnan kynnysarvon mittaamiseksi henkilöillä, joilla on ylipaino tai kohonnut sydän- ja sokeritaudin riski | |
| Açıkgöz et al. | Comparison of MDRD formula with creatinine clearance in estimation of glomerular filtration rate | |
| JP2015524465A5 (hr) | ||
| Christensen | Maternal occupational exposure during pregnancy and the risk of allergic disease in the children | |
| JP2017520513A5 (hr) | ||
| BR112016018009A8 (pt) | composição de cinamaldeído e zinco e seu uso | |
| Taraseviciene-Stewart et al. | Pathogenesis Of Pulmonary Hypertension: Adenine Nucleotides, T Cells And Endothelial Cell Proliferation | |
| Kulikov et al. | PHARMACOECONOMIC ANALYSIS OF NEUROPROTECTIVE DRUGS IN THE TREATMENT OF ACUTE DISORDERS OF CEREBRAL CIRCULATION | |
| IANTHROPOMETRIC | MARWAHA, et al. LEAN MASS IN INDIAN ADOLESCENTS | |
| CN302413456S (zh) | 身体成分分析仪 | |
| ES2526105R2 (es) | Composición emulsionada de grasa saturada en agua, su preparación y utilización para la evaluación de la tolerancia a los triglicéridos | |
| 陈梅琴 | The effect of non-alcoholic fatty liver disease on virologic response in patients with hepatitis B e antigen-positive chronic hepatitis B treated with nucleoside analogues | |
| CN302536626S (zh) | 分析物测试仪 | |
| CN302222409S (zh) | 卫生巾 | |
| Al-Asadi | Reflections on Falling Apart self in Al-Ma’ari’s Baghdadiyat | |
| CN302362853S (zh) | 浴室用花洒 |